Brookstone Capital Management Sells 2,151 Shares of United Therapeutics Corporation $UTHR

Brookstone Capital Management trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 32.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,471 shares of the biotechnology company’s stock after selling 2,151 shares during the period. Brookstone Capital Management’s holdings in United Therapeutics were worth $2,651,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,540,358.40. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 633,718 shares of company stock worth $358,492,749 over the last quarter. Corporate insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Stock Up 1.0%

United Therapeutics stock opened at $549.66 on Thursday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The stock has a market capitalization of $23.33 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.57. The stock has a 50-day simple moving average of $562.63 and a 200 day simple moving average of $525.08.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $6.63 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 26.49 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.